Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + SBRT in mRCC
NCT03469713Phase 2Completed
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
- Start
- Jul 2017
- Primary completion
- Mar 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in metastatic renal cell carcinoma (mRCC), sponsored by Gruppo Oncologico Italiano di Ricerca Clinica. Started Jul 2017; status: completed.
02
Drugs
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT03469713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03469713.